Toxicology – Dantrolene

Core Concept

Dantrolene is a direct-acting skeletal muscle relaxant and the specific treatment for malignant hyperthermia (MH).

Its major action is to reduce abnormal calcium release from skeletal-muscle sarcoplasmic reticulum.

In toxicology, dantrolene has also been used as an adjunct for severe muscle rigidity and hyperthermia in selected conditions such as neuroleptic malignant syndrome (NMS). However, older recommendations for routine use in serotonin syndrome, stimulant poisoning, carbon monoxide poisoning, or MAOI poisoning are not supported as standard modern therapy.

Mechanism of Action

Dantrolene acts primarily on skeletal muscle rather than the CNS.

It inhibits excessive calcium release through the skeletal-muscle ryanodine receptor (RyR1).

The sequence is:

↓ sarcoplasmic-reticulum Ca²⁺ release → ↓ intracellular Ca²⁺ → ↓ excitation–contraction coupling → ↓ muscle contraction and heat production

This explains its effectiveness in malignant hyperthermia.

Effect on Muscle

Dantrolene decreases the strength of skeletal-muscle contraction.

This can reduce:

• Rigidity
• Muscle-generated heat
• Excessive metabolic activity
• Rhabdomyolysis associated with sustained contraction

However, excessive effect can also produce clinically important muscle weakness.

Malignant Hyperthermia

Malignant hyperthermia is a potentially fatal hypermetabolic skeletal-muscle disorder occurring in genetically susceptible individuals after exposure to certain anesthetic triggers.

Important triggers include:

• Volatile inhalational anesthetics
• Succinylcholine

Abnormal RyR1-mediated calcium release causes uncontrolled skeletal-muscle metabolism.

Clinical Features of Malignant Hyperthermia

Possible findings include:

• Rapidly increasing end-tidal CO₂
• Tachycardia
• Muscle rigidity
• Masseter rigidity
• Metabolic acidosis
• Respiratory acidosis
• Hyperkalemia
• Rhabdomyolysis
• Rising creatine kinase
• Myoglobinuria
• Dysrhythmias
• Hyperthermia

A major high-yield point:

Hyperthermia may be a relatively late finding.

Do not wait for an extreme temperature before considering malignant hyperthermia.

Why CO₂ Is Important

Rapidly increasing CO₂ production is often an early manifestation of the hypermetabolic state.

During anesthesia, an otherwise unexplained rise in end-tidal CO₂ despite adequate ventilation is an important warning sign.

This may precede dramatic hyperthermia.

Treatment of Malignant Hyperthermia

Immediate priorities include:

• Stop triggering anesthetic agents.
• Give IV dantrolene promptly.
• Hyperventilate with high-concentration oxygen.
• Actively cool the patient when significantly hyperthermic.
• Treat hyperkalemia.
• Correct severe acidosis when appropriate.
• Treat dysrhythmias.
• Manage rhabdomyolysis and renal complications.
• Monitor closely for recurrence.

Dantrolene is central to treatment but does not replace resuscitative and supportive care.

Dantrolene Administration Principle

Dantrolene is administered promptly and repeatedly according to the patient’s clinical response until the hypermetabolic syndrome is controlled.

Because available formulations differ in concentration and reconstitution requirements, current product-specific malignant-hyperthermia protocols should be followed rather than older fixed preparation instructions.

Exact emergency dosing is best taken from the current institutional/MH protocol.

Recurrence of Malignant Hyperthermia

Symptoms can recur after initial stabilization.

Therefore, successful initial treatment does not mean monitoring can immediately stop.

Continued observation and additional dantrolene may be required according to the patient’s course.

Monitoring After Malignant Hyperthermia

Follow:

• Core temperature
• Continuous ECG
• End-tidal CO₂ when ventilated
• Blood pressure
• Potassium
• Blood gas
• Creatine kinase
• Renal function
• Urine output
• Evidence of myoglobinuria
• Coagulation studies in severe disease

Severe MH can cause multiorgan complications.

Neuroleptic Malignant Syndrome

NMS is usually associated with:

• Dopamine receptor blockade

or

• Abrupt withdrawal/reduction of dopaminergic therapy

Typical manifestations include:

• Hyperthermia
• Severe generalized rigidity
• Altered mental status
• Autonomic instability
• Elevated CK
• Rhabdomyolysis

Dantrolene in NMS

Dantrolene may be considered as an adjunct in severe NMS, particularly when prominent rigidity and hyperthermia are present.

However, unlike malignant hyperthermia:

Dantrolene is not a universally required or uniquely definitive antidote for NMS.

Core treatment remains:

• Stop the causative medication.
• Provide aggressive supportive care.
• Correct fluid and electrolyte abnormalities.
• Control severe hyperthermia.
• Treat complications.

Selected severe cases may also involve agents such as bromocriptine or amantadine and specialist-directed therapy.

Malignant Hyperthermia vs NMS

Although both can cause rigidity and hyperthermia, they are different syndromes.

Malignant Hyperthermia

Usually:

• Triggered by certain anesthetics/succinylcholine
• Rapid onset
• Direct skeletal-muscle calcium dysregulation
• Dantrolene is specific treatment

NMS

Usually:

• Related to dopamine blockade or dopaminergic withdrawal
• Evolves over a longer period
• CNS dopamine dysfunction is central
• Dantrolene is an optional adjunct rather than universally required

Serotonin Syndrome

The older source proposed dantrolene for serotonin syndrome.

This is not standard modern treatment.

Serotonin syndrome is characterized particularly by:

• Agitation
• Hyperreflexia
• Clonus
• Tremor
• Autonomic hyperactivity
• Hyperthermia in severe cases

Treatment emphasizes:

• Stop serotonergic drugs.
• Benzodiazepines for agitation and muscle activity.
• Aggressive cooling.
• IV fluids/supportive care.
• Cyproheptadine in selected cases.

Severe Serotonin-Syndrome Hyperthermia

Extreme hyperthermia is largely generated by excessive muscular activity.

In severe cases, management may require:

• Airway control
• Deep sedation
• Nondepolarizing neuromuscular paralysis
• Aggressive external cooling

Dantrolene has not demonstrated a sufficiently established benefit to be routine therapy.

Stimulant Toxicity

Older reports suggested dantrolene for hyperthermia caused by:

• Cocaine
• Amphetamines

Modern treatment instead emphasizes:

• Benzodiazepine sedation
• Rapid external cooling
• IV supportive care
• Treatment of seizures
• Management of cardiovascular complications

If life-threatening hyperthermia persists because of uncontrolled muscle activity, advanced airway management and neuromuscular paralysis may be necessary.

Dantrolene is not routinely recommended simply because stimulant toxicity causes hyperthermia.

MAOI Poisoning

MAOI toxicity can produce:

• Agitation
• Hyperthermia
• Hypertension or hypotension
• Neuromuscular abnormalities
• Seizures
• Serotonergic features

Management is predominantly aggressive supportive care.

Dantrolene is not a routine antidote for MAOI poisoning.

Carbon Monoxide Poisoning

The historical suggestion that dantrolene may treat carbon monoxide poisoning is not part of standard modern management.

CO poisoning is managed with:

• Immediate removal from exposure
• High-concentration oxygen
• Supportive care
• Hyperbaric oxygen in selected severe cases

Dantrolene does not reverse carboxyhemoglobin formation or the fundamental toxic mechanism of CO.

When Dantrolene Is Unlikely to Help

Dantrolene is most logical when excessive skeletal-muscle calcium release and contraction are major drivers of the syndrome.

It does not directly correct hyperthermia caused primarily by:

• Reduced sweating in anticholinergic poisoning
• Environmental heat exposure
• Salicylate-induced metabolic hyperthermia
• Thyroid hormone excess
• Infection or fever

The cause of hyperthermia determines treatment.

Dantrolene Is Not an Antipyretic

Dantrolene does not lower temperature by resetting the hypothalamic temperature set point.

Its benefit in MH comes from reducing skeletal-muscle heat generation.

Similarly, conventional antipyretics such as acetaminophen are generally ineffective for toxicologic hyperthermia because these syndromes are not ordinary fever.

Adverse Effects

Important adverse effects include:

• Muscle weakness
• Fatigue
• Dizziness
• Nausea
• Diarrhea
• Sedation
• Respiratory muscle weakness

In critically ill patients, additional weakness can complicate ventilation and recovery.

Hepatotoxicity

Dantrolene can cause liver injury.

Risk is primarily associated with longer-term oral therapy, rather than the short emergency courses used for malignant hyperthermia.

Potential abnormalities include:

• Elevated aminotransferases
• Hepatitis
• Rare severe hepatic injury

Liver function becomes particularly important with prolonged therapy.

Respiratory Effects

Because dantrolene weakens skeletal muscle, excessive treatment can worsen:

• Respiratory muscle weakness
• Ability to cough
• Ventilatory reserve

Patients with severe underlying neuromuscular or respiratory dysfunction therefore require careful monitoring.

Cardiovascular Considerations

Hemodynamic abnormalities can occur during severe illness or treatment.

An especially important interaction is with some calcium channel blockers, particularly verapamil, where combined use with dantrolene has been associated with serious cardiovascular effects and hyperkalemia.

This interaction is particularly relevant in malignant-hyperthermia management.

Pulmonary Edema – Historical Context

Older dantrolene formulations required substantial amounts of diluent, and large-volume administration could contribute to fluid burden.

Newer concentrated formulations may require considerably less volume.

Therefore, fluid-related complications depend partly on the formulation being used.

Pregnancy

The old FDA Category C classification is obsolete.

If malignant hyperthermia develops during pregnancy or around delivery, the maternal emergency requires prompt treatment.

Dantrolene should not be withheld when clinically necessary for malignant hyperthermia.

Chronic Dantrolene Therapy

Outside acute toxicology, oral dantrolene can be used for selected disorders involving chronic spasticity.

Long-term therapy differs substantially from emergency MH treatment and requires particular attention to:

• Liver function
• Muscle weakness
• Functional impairment
• Medication interactions

Important Modernization of the Older Source

Several older recommendations need correction:

• Malignant hyperthermia is the major established emergency indication for dantrolene.
• Dantrolene acts mainly through skeletal-muscle RyR1 inhibition, reducing sarcoplasmic-reticulum calcium release.
• Hyperthermia may occur late in MH; rising end-tidal CO₂, tachycardia, rigidity, acidosis, and hyperkalemia may appear earlier.
• Dantrolene can be considered in severe NMS but is an adjunct rather than an obligatory antidote.
• Dantrolene is not routine treatment for serotonin syndrome.
• It is not standard therapy for stimulant-induced hyperthermia, MAOI poisoning, or carbon monoxide poisoning.
• Severe serotonin or stimulant hyperthermia is managed primarily with sedation, aggressive cooling, and, when necessary, nondepolarizing neuromuscular paralysis.
• Dantrolene does not substitute for rapid external cooling or general critical care.
• Antipyretics do not effectively treat muscle-generated toxicologic hyperthermia.
• Modern dantrolene formulations differ, so historical reconstitution volumes and fixed preparation instructions should not be generalized.
• Hepatotoxicity is predominantly a concern with prolonged treatment rather than short emergency MH therapy.

Key Points

• Dantrolene is the specific drug treatment for malignant hyperthermia.
• It acts directly on skeletal muscle by reducing RyR1-mediated calcium release from the sarcoplasmic reticulum.
• This decreases muscle contraction, metabolism, and heat production.
• Malignant hyperthermia can initially present with rising end-tidal CO₂, tachycardia, rigidity, acidosis, and hyperkalemia before dramatic hyperthermia develops.
• Stop triggering anesthetics and administer dantrolene promptly when MH is suspected.
• Aggressive supportive care, cooling, electrolyte management, and treatment of rhabdomyolysis remain essential.
• MH can recur after initial control, so continued monitoring is necessary.
• Dantrolene may be considered as an adjunct for severe NMS, especially with marked rigidity and hyperthermia.
• It is not standard therapy for serotonin syndrome.
• It is not routinely indicated for cocaine/amphetamine hyperthermia, MAOI poisoning, carbon monoxide poisoning, anticholinergic hyperthermia, or heat stroke.
• Severe toxicologic hyperthermia caused by excessive muscle activity may require sedation, cooling, airway management, and nondepolarizing paralysis.
• Important adverse effects include muscle weakness and respiratory impairment.
• Hepatotoxicity is mainly associated with prolonged therapy.
• Dantrolene treats the muscular mechanism of MH; it is not a general-purpose treatment for every form of hyperthermia.